Increase Success in Drug Discovery While Reducing Time and Cost with RepliGut®
Altis Biosystems has created a next-generation in vitro platform that reduces the time and cost of developing safer, more effective drugs.
By replicating native human biology, the intestinal stem cell platform produces more accurate and reproducible data for better clinical trial performance and reduces the need for animal testing.
The RepliGut® model is a unique, stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.
With a scalable platform, actionable data, high throughput screening to test compounds, and an unrivaled biobank of ethically derived donor intestinal cells, the RepliGut® model is the future of in vitro testing during drug development.
The RepliGut® is a reproducible and scalable platform that is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.
Intestinal Barrier Function
Maintains barrier integrity with high TEER values
Comprised of polarized intestinal cells grown on transwells
Screen compounds for drug-induced GI toxicity early
Intestinal Drug Disposition
Developed to replace Caco-2 cells (cancer cells) and animals
NEWS AND ARTICLES
September 19, 2022
Predicting Clinical GI Safety Outcomes Using an in vitro Human Intestinal Epithelial Model
August 8, 2022
Webinar: Assessing Drug-induced Gut Toxicity In Vitro
Many promising new drugs fail human clinical trials due to a lack of efficacy or unanticipated toxicity. More predictive non-clinical models that reprise human physiology and accurately evaluate drug pharmacokinetics and safety are urgently needed. Building on organ-on-a-chip technology, researchers developed an intestine-on-a-chip that recapitulates the human gut. In this webinar, Bill Thelin, Ph.D, Chief Scientific Officer, Altis Biosystems discusses how intestine-on-a chip technology reliably models gastrointestinal disease and assists researchers in screening for safe, effective therapeutic candidates.Watch Video
June 25-30, 2023
2023 MPS World Summit
Have a question? Want to stay informed about Altis, RepliGut, and more platforms currently under development? Send us a message!